Studies have shown that TET2 and DNMT3A mutations (29, 32, 34) are linked to improved response to HMAs in MDS and related disorders; P53 mutation also predicted 5-AZA-dC -induced complete remission in patients with MDS (35). Here, TP53 is linked to myelodysplastic syndrome.